DOCKET NO

N THE UNITED STATES PATENT AND TRADEMARK OFFI

Applicant: Chow et al. Serial No.: 09/815,362 Filed: March 21, 2001 COMPOUNDS AND METHOD OF For: TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE

AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS

Group Art Unit: 1626

Examiner:

Not Yet Assigned

first class Initial Patent Examination, Center, Washington, D.C. 20231 on:

10/25

STATEMENT OF STEPHEN A. MUNK

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

I, Stephen A. Munk, am an inventor of the subject matter claimed in the above-referenced patent application.

While at the time the invention was made I was employed by Allergan, Inc., the parent company of the assignee Allergan Sales, Inc., I have not been employed by Allergan for some years. Consequently, I was unaware that this continuing application was filed until after the filing date, and therefore had no opportunity to advise Allergan that the inventor information, including the list of inventors, was incomplete. Thus, the incorrect naming of the inventive entity in this patent application was made without deceptive intent on my part; moreover, it is my understanding that such incorrect indication of inventors was an inadvertent error made when the patent application was filed.

Respectfully submitted,

Dated: Souther 2007





DEC 3 1 2001

E UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

	IN THE UNITED	STATES PATERITAIND TRA	ADEMIARK OFFICE	
Applicant:	Chow et al.		deposited with the United S	correspondence is being States Postal Service as first
Serial No.:	09/815,362) Commissioner for Patent	e addressed to: Assistant is, Office of Initial Patent ervice Center, Washington,
Filed:	March 21, 2001		D.C. 20231 on:	25/01
For:	COMPOUNDS AND METHO	DD OF	(Date o	Deposit)
TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE			Donnie	rensuson
AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS) Printed Name of Person	Making Deposit
Group Art Unit: 1626			Donn	e Flegu
Examiner:	Not Yet Assigned		10/	2.5/0/
			/Dafe of	Signature

CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

As owner of the entire right, title, and interest in the above identified patent application, ALLERGAN hereby consents to the correction of inventorship to add Stephen A. Munk as an inventor in the above-referenced patent application . ALLERGAN'S right to take action pursuant to 37 CFR 3.73 is established in an Assignment from the inventors to ALLERGAN recorded in the Patent and Trademark Office on August 16, 1996 at Reel 8135, Frame 0552.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan Sales, Inc.

Respectfully submitted,

Martin A. Voet Assistant Secretary Allergan Sales, Inc. 2525 Dupont Drive Invine CA 92612